Summary
The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Questions Answered:
- What was the size of the NAFTA generics market by value in 2017?
- What will be the size of the NAFTA generics market in 2022?
- What factors are affecting the strength of competition in the NAFTA generics market?
- How has the market performed over the last five years?
- How large is the NAFTA generics market in relation to its regional counterparts?
Scope
Essential resource for top-line data and analysis covering the NAFTA generics market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.
- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of $1,13,947.8 million in 2017.The Mexico was the fastest growing country, with a CAGR of 14.7% over the 2013-17 period.
- Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of $1,02,919.9 million in 2017. This was followed by Mexico and Canada, with a value of $6,014.0 and $5,014.0 million, respectively.
- The US is expected to lead the generics industry in the NAFTA bloc, with a value of $1,30,127.0 million in 2022, followed by Mexico and Canada with expected values of $9,175.2 and $5,616.0 million, respectively.
Reasons to buy
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market
- Leading company profiles reveal details of key generics market players’ NAFTA operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts by both value and volume
- Compares data from the US, Canada and Mexico, alongside individual chapters on each country
'
Table of Contents
Introduction 8
What is this report about? 8
Who is the target reader? 8
How to use this report 8
Definitions 8
NAFTA Generics 9
Industry Outlook 9
Generics in Canada 12
Market Overview 12
Market Data 13
Market Segmentation 15
Market outlook 16
Five forces analysis 18
Macroeconomic indicators 25
Generics in Mexico 27
Market Overview 27
Market Data 28
Market Segmentation 30
Market outlook 31
Five forces analysis 33
Macroeconomic indicators 39
Generics in The United States 41
Market Overview 41
Market Data 42
Market Segmentation 44
Market outlook 45
Five forces analysis 47
Macroeconomic indicators 53
Company Profiles 55
Leading Companies 55
Appendix 72
Methodology 72
About MarketLine 73
List of Tables
Table 1: NAFTA countries generics industry, revenue ($m), 2013-22
Table 2: NAFTA countries generics industry, revenue ($m), 2013-17
Table 3: NAFTA countries generics industry forecast, revenue ($m), 2017-22
Table 4: Canada generics market value: $ million, 2013-17
Table 5: Canada generics market volume: % of total pharma, 2013-17
Table 6: Canada generics market geography segmentation: $ million, 2017
Table 7: Canada generics market value forecast: $ million, 2017-22
Table 8: Canada generics market volume forecast: % of total pharma, 2017-22
Table 9: Canada size of population (million), 2013-17
Table 10: Canada gdp (constant 2005 prices, $ billion), 2013-17
Table 11: Canada gdp (current prices, $ billion), 2013-17
Table 12: Canada inflation, 2013-17
Table 13: Canada consumer price index (absolute), 2013-17
Table 14: Canada exchange rate, 2013-17
Table 15: Mexico generics market value: $ million, 2013-17
Table 16: Mexico generics market volume: % of total pharma, 2013-17
Table 17: Mexico generics market geography segmentation: $ million, 2017
Table 18: Mexico generics market value forecast: $ million, 2017-22
Table 19: Mexico generics market volume forecast: % of total pharma, 2017-22
Table 20: Mexico size of population (million), 2013-17
Table 21: Mexico gdp (constant 2005 prices, $ billion), 2013-17
Table 22: Mexico gdp (current prices, $ billion), 2013-17
Table 23: Mexico inflation, 2013-17
Table 24: Mexico consumer price index (absolute), 2013-17
Table 25: Mexico exchange rate, 2013-17
Table 26: United States generics market value: $ billion, 2013-17
Table 27: United States generics market volume: % of total pharma, 2013-17
Table 28: United States generics market geography segmentation: $ billion, 2017
Table 29: United States generics market value forecast: $ billion, 2017-22
Table 30: United States generics market volume forecast: % of total pharma, 2017-22
Table 31: United States size of population (million), 2013-17
Table 32: United States gdp (constant 2005 prices, $ billion), 2013-17
Table 33: United States gdp (current prices, $ billion), 2013-17
Table 34: United States inflation, 2013-17
Table 35: United States consumer price index (absolute), 2013-17
Table 36: United States exchange rate, 2013-17
Table 37: Apotex, Inc.: key facts
Table 38: Mylan N.V.: key facts
Table 39: Mylan N.V.: key financials ($)
Table 40: Mylan N.V.: key financial ratios
Table 41: Novartis AG: key facts
Table 42: Novartis AG: key financials ($)
Table 43: Novartis AG: key financial ratios
Table 44: Pfizer Inc.: key facts
Table 45: Pfizer Inc.: key financials ($)
Table 46: Pfizer Inc.: key financial ratios
Table 47: Teva Pharmaceutical Industries Limited: key facts
Table 48: Teva Pharmaceutical Industries Limited: key financials ($)
Table 49: Teva Pharmaceutical Industries Limited: key financial ratios
List of Figures
Figure 1: NAFTA countries generics industry, revenue ($m), 2013-22
Figure 2: NAFTA countries generics industry, revenue ($m), 2013-17
Figure 3: NAFTA countries generics industry forecast, revenue ($m), 2017-22
Figure 4: Canada generics market value: $ million, 2013-17
Figure 5: Canada generics market volume: % of total pharma, 2013-17
Figure 6: Canada generics market geography segmentation: % share, by value, 2017
Figure 7: Canada generics market value forecast: $ million, 2017-22
Figure 8: Canada generics market volume forecast: % of total pharma, 2017-22
Figure 9: Forces driving competition in the generics market in Canada, 2017
Figure 10: Drivers of buyer power in the generics market in Canada, 2017
Figure 11: Drivers of supplier power in the generics market in Canada, 2017
Figure 12: Factors influencing the likelihood of new entrants in the generics market in Canada, 2017
Figure 13: Factors influencing the threat of substitutes in the generics market in Canada, 2017
Figure 14: Drivers of degree of rivalry in the generics market in Canada, 2017
Figure 15: Mexico generics market value: $ million, 2013-17
Figure 16: Mexico generics market volume: % of total pharma, 2013-17
Figure 17: Mexico generics market geography segmentation: % share, by value, 2017
Figure 18: Mexico generics market value forecast: $ million, 2017-22
Figure 19: Mexico generics market volume forecast: % of total pharma, 2017-22
Figure 20: Forces driving competition in the generics market in Mexico, 2017
Figure 21: Drivers of buyer power in the generics market in Mexico, 2017
Figure 22: Drivers of supplier power in the generics market in Mexico, 2017
Figure 23: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2017
Figure 24: Factors influencing the threat of substitutes in the generics market in Mexico, 2017
Figure 25: Drivers of degree of rivalry in the generics market in Mexico, 2017
Figure 26: United States generics market value: $ billion, 2013-17
Figure 27: United States generics market volume: % of total pharma, 2013-17
Figure 28: United States generics market geography segmentation: % share, by value, 2017
Figure 29: United States generics market value forecast: $ billion, 2017-22
Figure 30: United States generics market volume forecast: % of total pharma, 2017-22
Figure 31: Forces driving competition in the generics market in the United States, 2017
Figure 32: Drivers of buyer power in the generics market in the United States, 2017
Figure 33: Drivers of supplier power in the generics market in the United States, 2017
Figure 34: Factors influencing the likelihood of new entrants in the generics market in the United States, 2017
Figure 35: Factors influencing the threat of substitutes in the generics market in the United States, 2017
Figure 36: Drivers of degree of rivalry in the generics market in the United States, 2017
Figure 37: Mylan N.V.: revenues & profitability
Figure 38: Mylan N.V.: assets & liabilities
Figure 39: Novartis AG: revenues & profitability
Figure 40: Novartis AG: assets & liabilities
Figure 41: Pfizer Inc.: revenues & profitability
Figure 42: Pfizer Inc.: assets & liabilities
Figure 43: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 44: Teva Pharmaceutical Industries Limited: assets & liabilities
